nqo2

Dabigatran ethyl ester hydrochloride 是一种核糖基二氢烟酰胺脱氢酶抑制剂，IC50=0.8 μM，也是一种凝血酶的抑制剂。

NQO2-IN-1是一种白藜芦醇（resveratrol）类似物，是有效的醌氧化还原酶2（NQO2）抑制剂（IC50=95 nM），通过产生ROS和上调DR5（death receptor 5）逆转trial耐药性并促进细胞凋亡，具有抗肿瘤的潜力。

Nrf2-ARE hMAO-B QR2 modulator 1是白藜芦醇 (Resveratrol)衍生物和多靶标定向配体（mtdl），激活NRF2-ARE通路（CD = 9.83 μM），选择性抑制hMAO-B和QR2（quinone reductase-2，NQO2） (IC 50 = 8.05和0.57 μM)，能够促进海马神经发生，在阿尔茨海默病模型中发挥神经保护和抗氧化作用。

Tubulin inhibitor 14 是一种有效的 NQO2（醌氧化还原酶 2）抑制剂，IC50 为 1.0 μM，也抑制微管蛋白聚合和内皮细胞毛细管样管的形成。Tubulin inhibitor 14 是一种微管去稳定剂，具有潜在的肿瘤选择性以及抗血管生成和血管破坏的功能[1]。

Tretazicar (NSC-115829) 是一种抗肿瘤前药，由 NAD(P)H 醌氧化还原酶 2 激活。它在酶促活化后生成细胞毒性双功能烷基剂，可以形成 DNA-DNA 链间交联。

Caricotamide is a synthetic co-substrate that activates the human endogenous enzyme NRH:quinone oxidoreductase 2 (NQO2) with potential chemoadjuvant activity. When caricotamide is administered simultaneously with the prodrug tretazicar, NQO2 converts tretazicar to the bifunctional alkylating agent dinitrobenzamide, which is capable of forming a high degree of DNA interstrand cross-links, resulting in the inhibition of DNA replication and the induction of apoptosis. NQO2 has been found to be over-expressed in cancers such as hepatocellular carcinoma (HCC), colorectal and ovarian cancers.